Swan Capital’s Fortress Biotech FBIO Stock Holding History

Swan Capital’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-250	Closed	-$924	–	525
2025 Q3	$924	Buy	+250	New	+$632	﹤0.01%	401

Other funds holding FBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Swan Capital's FBIO Position: Q4 2025 in Review

Swan Capital sold out of Fortress Biotech (FBIO) in Q4 2025, closing a stake of 250 shares — an estimated $924 sold.

Swan Capital first reported a position in FBIO in Q3 2025 and held it in 1 quarter. The position peaked at $924 in Q3 2025. 52 funds tracked by Wall St. Rank hold FBIO as of Q4 2025.

Swan Capital reported no remaining Fortress Biotech position as of Q4 2025 after selling out during the quarter.
Swan Capital sold 250 Fortress Biotech shares in Q4 2025, an estimated $924.
Swan Capital first reported a position in Fortress Biotech in Q3 2025 and held it in 1 quarter.
Swan Capital's Fortress Biotech position peaked at $924 in Q3 2025.
52 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2025.

Based on Swan Capital's 13F filing for Q4 2025, filed 12 Feb 2026.